UMIN-CTR History

Name:  UMIN ID:


Unique ID issued by UMIN UMIN000033351
Receipt number R000037897
Scientific Title A Phase I study of Inotuzumab Ozogamicin as a single agent for pediatric patients in Japan with relapsed/refractory CD22-positive Acute Lymphoblastic Leukemia
Date of disclosure of the study information 2018/07/20
Last modified on 2021/07/12 14:30:14

No. Disposal Last modified on Item of update
1 Insert 2018/07/10 14:56:33
2 Update 2018/07/10 15:20:09 Interventions/Control_1
3 Update 2018/09/18 16:56:40 Recruitment status
4 Update 2019/10/31 16:56:57 Key inclusion criteria
Key inclusion criteria
5 Update 2019/10/31 17:12:31 1st name of lead principal investigator
Last name of lead principal investigator
1st name of lead principal investigator
Last name of lead principal investigator
Zip code

Last name of contact person

Last name of contact person
Zip code
Institute
Institute
Organization
Organization
Address
Address
Tel
Email
Institutions
6 Update 2019/10/31 17:17:36 Email1
Email
7 Update 2020/03/24 09:51:55 Recruitment status
Date of IRB
Last follow-up date
8 Update 2021/02/10 15:12:24 UMIN ID2
9 Update 2021/07/12 14:30:14 Recruitment status